News › Clinical Practice, Industry News

Lilly Sues Two Compounders Over Copies of Weight-loss Drugs

April 2, 2025

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.

This comes after a U.S. federal judge last month refused to allow compounding pharmacies to keep making copies of these drugs in the United States.

Compounders had been allowed to produce hundreds of thousands of doses of copies of obesity drugs only while the FDA said there was a shortage of them.

Lilly said the companies were selling unapproved drugs and making false claims about efficacy and safety.

The drugmaker says it will also send about fifty cease and desist letters to compounders and telehealth companies, asking them to confirm that they have already ceased mass compounding.

Read full coverage at Reuters >>

Find the latest updates on tirzepatide and semaglutide at our resource page: Medical Weight Loss in a Med Spa Practice.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical
    • Botox Cosmetic’s “The Confidence Collective” to Empower 250 Women Entrepreneurs
    • Medical Spa Show 2027 Call for Presentations Now Open
    • FDA Warning Letter to Texas Medical Spa Signals Increased Compliance Enforcement